Wilhelm Barbara, Kellert Renate, Schnell Rainer, Lüdtke Holger, Petrini Orlando
STZ eyetrial at the Centre for Ophthalmology, University Tübingen, Schleichstr. 12-16, 72076 Tübingen, Germany.
Psychopharmacology (Berl). 2009 Sep;205(4):679-88. doi: 10.1007/s00213-009-1576-6. Epub 2009 Jun 24.
An objective physiological test was used to investigate the hangover effect, its time course and dose relationship compared to placebo and an herbal relaxant.
Pupillographic Sleepiness Test as an objective measurement, Stanford Sleepiness Scale (SSS) and visual analogue scales (VAS) were used. Study design included: (a) randomised, double-blind, double-dummy, placebo-controlled crossover trial; (b) double-blind, placebo-controlled, randomised study. Primary end point was the Pupillary Unrest Index (lnPUI).
Oxazepam 10 mg did not increase PUI. In the VAS and SSS, there was no increase in sleepiness after the three treatment periods. Neither 10 nor 30 mg oxazepam caused sedation in healthy volunteers. Subjective and objective sleepiness measures correlated significantly.
The lack of sedative effects after vespertine intake of oxazepam (10/30 mg) seems to be relevant with respect to product safety. With regard to the subjective perception at 30 mg, fatigue rather than sleepiness may be the underlying reason.
采用客观生理学测试方法,研究宿醉效应、其时间进程以及与安慰剂和一种草本放松剂相比的剂量关系。
使用瞳孔嗜睡测试作为客观测量方法,同时采用斯坦福嗜睡量表(SSS)和视觉模拟量表(VAS)。研究设计包括:(a)随机、双盲、双模拟、安慰剂对照交叉试验;(b)双盲、安慰剂对照、随机研究。主要终点是瞳孔不安指数(lnPUI)。
10毫克奥沙西泮未增加PUI。在VAS和SSS中,三个治疗期后嗜睡程度均未增加。10毫克和30毫克奥沙西泮均未对健康志愿者产生镇静作用。主观和客观嗜睡测量结果显著相关。
傍晚服用奥沙西泮(10/30毫克)后缺乏镇静作用似乎与产品安全性相关。就30毫克时的主观感受而言,疲劳而非嗜睡可能是潜在原因。